First line hypertension drug
First-line antihypertensive drugs generally fall into four main classes: ACE inhibitors (e.g. ramipril), ARBs (e.g. losartan), calcium channel blockers (e.g. amlodipine), and thiazide diuretics (e.g. hydrochlorothiazide). Beta-blockers were previously first-line but are now reserved for specific indications. Choice depends on patient age, ethnicity, comorbidities, and tolerability.
Searching sources...
Reading File
Searching PubMed
"hypertension" AND "first-line" AND "antihypertensive"
Now let me search the medical library for antihypertensive drug content.
Finding Sources
Searching the Web
first line hypertension drugs 2024 2025 guidelines JNC AHA ACC
Finding Sources
Reading File
Reading File
Here is a thorough, guideline-based summary of first-line antihypertensive drugs:
First-Line Drugs for Hypertension
Per the 2025 AHA/ACC Guidelines (full guideline, Circulation 2025;152:1-105), four drug classes are recommended as first-line therapy for primary (essential) hypertension:
The Four First-Line Classes
| Class | Prototype Examples | Typical Dose Range | Key Notes |
|---|---|---|---|
| Thiazide/Thiazide-like Diuretics | Hydrochlorothiazide, Chlorthalidone, Indapamide | 12.5-50 mg/day | Chlorthalidone preferred over HCTZ (longer acting, better outcomes data) |
| Long-acting Dihydropyridine CCBs | Amlodipine, Nifedipine ER | Amlodipine 2.5-10 mg/day | Excellent for elderly and isolated systolic HTN |
| ACE Inhibitors (ACEi) | Ramipril, Lisinopril, Enalapril | Lisinopril 10-40 mg/day | Mandatory in CKD with proteinuria, diabetes; avoid in pregnancy |
| Angiotensin Receptor Blockers (ARBs) | Losartan, Valsartan, Olmesartan | Losartan 50-100 mg/day | Use when ACEi causes intolerable cough; never combine ACEi + ARB |
Do NOT combine ACEi + ARB - the 2025 guidelines classify this as Class 3: Harm.
Dosing Algorithm by Stage
- Stage 1 HTN (SBP 130-139 / DBP 80-89 mmHg): Start with 1 first-line agent, titrate dose and add others sequentially as needed. Pharmacological treatment depends on CV risk - not always required.
- Stage 2 HTN (SBP ≥140 / DBP ≥90 mmHg): Start with 2 first-line agents of different classes, ideally as a single-pill combination to improve adherence.
Why Beta-Blockers Are NOT First-Line
Per Goldman-Cecil Medicine and Katzung's Pharmacology, beta-blockers were removed from first-line status because they are:
- Generally less effective at lowering BP than the four preferred classes
- Less protective against stroke compared to CCBs and thiazides
- Still indicated when a compelling indication exists (e.g., post-MI, heart failure with reduced ejection fraction, atrial fibrillation)
Comorbidity-Driven Drug Selection
Per Goodman & Gilman's and the 2025 AHA/ACC guideline:
| Comorbidity | Preferred Agent(s) |
|---|---|
| CKD with proteinuria / Diabetes | ACEi or ARB (first choice) |
| Coronary artery disease | ACEi or ARB + Beta-blocker |
| Heart failure (HFrEF) | ACEi/ARB + Beta-blocker + MRA |
| Elderly / Isolated systolic HTN | CCB or Thiazide |
| Stroke/TIA history | ACEi + Thiazide diuretic |
| Left ventricular hypertrophy | ACEi, ARB, or CCB |
| Pregnancy | Labetalol or Nifedipine ER (ACEi/ARB are contraindicated) |
| Peripheral artery disease | ACEi or ARB |
| Benign prostatic hypertrophy | Alpha-1 blocker (doxazosin) - 2nd line adjunct |
Key Points from Pharmacology Textbooks
- Blood pressure lowering itself is the most important goal - large trials showed no major differences in outcome between the four classes in uncomplicated HTN (Goodman & Gilman's, 16th ed.)
- All four classes are available as low-cost generics, making cost a non-issue
- Prefer drugs with long half-lives (once-daily dosing) to improve compliance and achieve >50% trough-peak effect ratio
- Non-pharmacological therapy first: sodium restriction (<70-100 mEq/day), weight loss, DASH diet, exercise - these can normalize BP in up to 75% of overweight patients with mild-moderate HTN (Katzung, 16th ed.)
Sources: Katzung's Basic & Clinical Pharmacology (16e), Goodman & Gilman's Pharmacological Basis of Therapeutics, 2025 AHA/ACC Hypertension Guideline, NYC DOH 2025 Advisory
This is a shared conversation. Sign in to Orris to start your own chat.